Voluntary announcement - SYS6062 (antibody-drug conjugate) obtains clinical trial approval in China
Filed with HKEX · Stock code 1093 · · 1 page · English
Summary by 6ix AI
The product targets specific receptors on tumor cells to deliver toxins and is intended for treating advanced solid tumors. Preclinical studies have shown promising anti-tumor effects against various cancers, with expectations for favorable results in upcoming trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - data from Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer presented as a rapid oral presentation at the 2026 annual global meeting of the international gynecologic cancer society (igcs 2026)
- Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - results of phase III clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
- Voluntary announcement - Phase Ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in China
Later from CSPC Pharmaceutical
- Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China
- Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme
- Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme
- Voluntary announcement - phase i clinical trial of SYH2083 eye drops for the treatment of dry eye disease officially initiated in china
- Voluntary announcement - phase ii clinical trial of SYH2066 for the treatment of respiratory syncytial virus infection officially initiated in china
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical